Last reviewed · How we verify
Hydrocortisone 2.5%
Hydrocortisone is a glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Hydrocortisone is a glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and pruritic dermatological conditions (topical), Eczema, dermatitis, and other inflammatory skin disorders.
At a glance
| Generic name | Hydrocortisone 2.5% |
|---|---|
| Sponsor | University of the Pacific |
| Drug class | Glucocorticoid |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Hydrocortisone (cortisol) is an endogenous glucocorticoid that exerts anti-inflammatory and immunosuppressive effects by translocating to the nucleus and modulating gene expression of inflammatory mediators. It reduces vasodilation, decreases vascular permeability, and inhibits leukocyte migration and activation. At 2.5% concentration in topical formulation, it provides localized anti-inflammatory effects for dermatological conditions.
Approved indications
- Inflammatory and pruritic dermatological conditions (topical)
- Eczema, dermatitis, and other inflammatory skin disorders
Common side effects
- Skin atrophy
- Striae
- Telangiectasia
- Local irritation or burning
- Systemic absorption effects (with prolonged use)
Key clinical trials
- Microneedling for Burn Hypertrophic Scars (NA)
- Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) (PHASE1)
- A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) (PHASE2)
- Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis (PHASE4)
- V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency (PHASE3)
- Effects of Pregnancy-associated Hormones on THC Metabolism in Women (PHASE4)
- The Influence of Fluid Intake on Daily Biological Rhythm and Mental Performance in Healthy Young Adults (NA)
- Topical Treatment for TMJ Arthralgia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydrocortisone 2.5% CI brief — competitive landscape report
- Hydrocortisone 2.5% updates RSS · CI watch RSS
- University of the Pacific portfolio CI